GNI sharply extended gains, with the stock price of the reverse merger target subsidiary rising, resulting in a significant increase in equity valuation gains.

Fisco Japan · Nov 27, 2024 12:54

Significant continued growth. Information regarding questions and answers from investors has been disclosed. On the 14th, the consolidated subsidiary Cullgen reached a merger agreement by reverse merger with Pulmatrix, which is listed on the nasdaq, anticipating other revenue of approximately 14.7 billion 64 million yen (the stock valuation gain is expected to be approximately 10.7 billion 68 million yen). However, following the rise in Pulmatrix's stock price, it was replied in this disclosure that "the stock valuation gain we will report will also increase significantly," indicating a buying advantage.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

ＧＮＩ---大幅に続伸、連結子会社の逆さ合併先の株価上昇で「株式評価益も大幅増加」と回答

GNI sharply extended gains, with the stock price of the reverse merger target subsidiary rising, resulting in a significant increase in equity valuation gains.

Risk Disclaimer

Statement